Cowen and Company reaffirmed their hold rating on shares of PDL BioPharma, Inc. (NASDAQ:PDLI) in a report published on Friday, October 27th. They currently have a $3.00 price objective on the biotechnology company’s stock.
Several other analysts have also recently issued reports on PDLI. BidaskClub cut PDL BioPharma from a strong-buy rating to a buy rating in a research note on Tuesday, July 11th. ValuEngine raised PDL BioPharma from a hold rating to a buy rating in a report on Friday, August 4th. Piper Jaffray Companies reaffirmed a buy rating and set a $4.00 target price on shares of PDL BioPharma in a report on Thursday, August 10th. Finally, Zacks Investment Research raised PDL BioPharma from a hold rating to a buy rating and set a $3.00 target price for the company in a report on Wednesday, August 16th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $3.33.
PDL BioPharma (NASDAQ:PDLI) traded up $0.01 during trading hours on Friday, hitting $3.04. The company had a trading volume of 1,403,800 shares, compared to its average volume of 1,848,308. PDL BioPharma has a fifty-two week low of $1.93 and a fifty-two week high of $3.77. The firm has a market capitalization of $469.95, a PE ratio of 6.31 and a beta of 0.46. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.90 and a current ratio of 1.94.
PDL BioPharma (NASDAQ:PDLI) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.13 by $0.01. The firm had revenue of $62.75 million for the quarter, compared to analyst estimates of $61.86 million. During the same quarter in the previous year, the company earned $0.08 EPS. The company’s quarterly revenue was up 17.0% compared to the same quarter last year. equities research analysts expect that PDL BioPharma will post 0.69 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “PDL BioPharma, Inc. (PDLI) Receives “Hold” Rating from Cowen and Company” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/11/pdl-biopharma-inc-pdli-receives-hold-rating-from-cowen-and-company.html.
PDL BioPharma declared that its Board of Directors has initiated a share repurchase program on Monday, September 25th that allows the company to repurchase $25.00 million in shares. This repurchase authorization allows the biotechnology company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
A number of hedge funds have recently modified their holdings of PDLI. Credit Agricole S A boosted its stake in PDL BioPharma by 34.9% during the 1st quarter. Credit Agricole S A now owns 50,000 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 12,942 shares in the last quarter. Public Employees Retirement System of Ohio boosted its stake in PDL BioPharma by 15.3% during the 1st quarter. Public Employees Retirement System of Ohio now owns 55,423 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 7,336 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in PDL BioPharma during the 3rd quarter valued at $131,000. Airain ltd boosted its stake in PDL BioPharma by 21.0% during the 2nd quarter. Airain ltd now owns 56,911 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 9,893 shares in the last quarter. Finally, Two Sigma Securities LLC bought a new position in PDL BioPharma during the 1st quarter valued at $148,000. 82.69% of the stock is owned by institutional investors and hedge funds.
PDL BioPharma Company Profile
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.